[Federal Register Volume 77, Number 123 (Tuesday, June 26, 2012)]
[Notices]
[Pages 38065-38066]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-15574]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30-Day-12-12ET]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
(404) 639-7570 or send an email to [email protected]. Send written comments 
to CDC Desk Officer, Office of Management and Budget, Washington, DC 
20503 or by fax to (202) 395-5806. Written comments should be received 
within 30 days of this notice.

Proposed Project

    Communications Research for the Development of Messages and 
Materials about Cytomegalovirus (CMV)--NEW--Prevention Research Branch, 
National Center on Birth Defects and Developmental Disabilities 
(NCBDDD), Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    Cytomegalovirus (CMV) is the most common congenital infection in 
the U.S., causing disabilities in more than 5,500 children born each 
year (CDC, 2010). Disabilities related to congenital CMV are more 
common than other well-known childhood conditions, such as Down 
syndrome, fetal alcohol syndrome, and neural tube defects, and can 
include hearing or vision loss, mental retardation, psychomotor delays, 
and speech and language impairment.
    This is a multiphase communication research study that will help 
inform CDC's development of materials and prevention messaging about 
congenital CMV. The information collection activities will consist of 
two phases of research: Phase I will consist of focus groups and Phase 
II will consist of a web survey. First, we plan to conduct 8

[[Page 38066]]

focus groups with 9 respondents each to identify potential messaging 
frames for communicating information about congenital CMV to the target 
audiences and adopting CMV preventive guidelines. We will also conduct 
some preliminary testing of existing CDC CMV draft materials (factsheet 
and video). We estimate that we will screen 144 women in order to 
recruit 72 participants for the focus groups. These focus groups will 
be conducted in Atlanta, Georgia (4) and San Diego, California (4). 
Findings from the Phase I focus groups will inform refinements to 
existing CDC messages and materials (factsheet and video), which will 
be further tested in the second information collection activity, the 
web survey. Phase II research will include an online survey to test the 
refined communication interventions (factsheet and video). This web 
survey will: (1) Examine baseline awareness and knowledge regarding 
CMV, (2) assess baseline CMV prevention behaviors prior to viewing CMV 
communication interventions (factsheet and video), (3) assess appeal 
and evaluate the impact of CMV communication interventions on their 
attitudes, beliefs, and behavioral intentions regarding prevention 
behaviors and (4) assess knowledge, attitudes and behaviors pre- and 
post- interventions with a larger target audience sample (N=800). We 
estimate that we will screen 4,800 women in order to recruit 800 
respondents for the online survey.
    This request is submitted to obtain OMB clearance for two years. 
There are no costs to the respondents other than their time.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                      Average
                                                     Number of       Number of      burden per     Total burden
      Type of respondent            Form name       respondents    responses per   response  (in       hours
                                                                    respondent        hours)
----------------------------------------------------------------------------------------------------------------
                                              Phase I: Focus Groups
----------------------------------------------------------------------------------------------------------------
Women of childbearing age.....  Participant                  144               1            5/60              12
                                 screener.
                                Demographic                   72               1           15/60              18
                                 questionnaire.
                                Informed consent              72               1           15/60              18
                                 form.
                                Focus group.....              72               1           90/60             108
----------------------------------------------------------------------------------------------------------------
                                              Phase II: Web Survey
----------------------------------------------------------------------------------------------------------------
Women of childbearing age.....  Participant per            4,800               1            3/60             240
                                 screener.
                                Web Survey......             800               1           11/60             147
----------------------------------------------------------------------------------------------------------------


    Dated: June 18, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI), Office of the Associate 
Director for Science (OADS), Office of the Director, Centers for 
Disease Control and Prevention.
[FR Doc. 2012-15574 Filed 6-25-12; 8:45 am]
BILLING CODE 4163-18-P